If I'm reading that first graph correctly, which is for the whole tested population, the averaged pain reduction for iPPS is only at best about 6% less than the placebo. So what I'm interpreting is that for some severe pain sufferers a more substantial reduction is found ( previous announcement) , but averaged out over the whole population tested it does not look to be too impressive. Or am I dead wrong?
Ann: Paradigms Supplementary Phase 2B Data, page-4
-
- There are more pages in this discussion • 35 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
57.5¢ |
Change
0.080(16.2%) |
Mkt cap ! $82.30M | |||
| Open | High | Low | Value | Volume |
| 50.5¢ | 58.0¢ | 50.0¢ | $753.7K | 1.388M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3168 | 57.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 57.5¢ | 102000 | 2 |
View Market Depth
| Last trade - 12.31pm 04/12/2024 (20 minute delay) ? |
| PAR (ASX) Chart |
